BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Amgen (AMGN) Whistleblower Fights to Unseal Documents


1/15/2013 8:29:33 AM

Despite a $762 million settlement between Amgen and the US Department of Justice for off-label marketing of various medicines, the clash between the biotech and one of the whistleblowers is not over yet. A bitter dispute, in fact, continues to rage over an arbitration award – and the related proceedings – involving a former Amgen employee. The long-running battle has pitted the biotech against Elena Ferrante, who once worked as a sales rep promoting the Enbrel rheumatoid arthritis treatment, but claimed Amgen sales managers encouraged reps to promote off-label and encouraged physicians to prescribe Enbrel to patients who may not have needed the drug. She also maintained the reps were also instructed to cull patient medical records and give the information to Amgen, which violated the Health Insurance Portability and Accountability Act. In October 2006, Ferrante filed a complaint against the biotech for $10 million before an arbitrator, claiming she was fired in retaliation the year before for not complying with an allegedly improper marketing strategy. She was forced to seek arbitration because this requirement was imposed by Amgen (AMGN) on employees who filed such disputes. Recently, though, an arbitrator dismissed her claim. In response, Ferrante filed a lawsuit in state court in New Jersey, where she once worked as an Amgen sales rep, alleging that Amgen manipulated the arbitration process. According to the complaint, there were undisclosed relationships involving the arbitrator and attorneys for Amgen, and is she seeking to have the award overturned. Specifically, the complaint states the arbitrator, retired federal judge John Lifland, filed disclosures that were “misleading and incomplete.” He “failed to disclose that he had an ownership interest” in JAMS, the arbitration service chosen by Amgen, and as a result, he had a “financial interest in prolonging and complicating the proceeding as he got a percentage of all billings” generated by the long-running arbitration, the complaint states.

Read at Pharmalot

Pharmalot
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->